Revlon
This article was originally published in The Rose Sheet
Executive Summary
Chief Financial Officer and exec VP Thomas McGuire and President of International and exec VP David Kennedy will rotate their positions and responsibilities, enabling the company to benefit from the "varied and valuable experiences and perspectives" of each of the execs, Revlon announces Jan. 18. The strategy will be effective in March. Under McGuire's leadership, Revlon's "financial strength and flexibility have been significantly enhanced" through the successful implementation of the Sarbanes-Oxley compliance, while Kennedy has "successfully strengthened our international management team, reporting structures and controls and developed and implemented strategies that have restored growth to this key segment," Revlon President and CEO Jack Stahl says. "At the same time, Tom has strong overseas experience and David has a very solid background in finance," he points out. McGuire, who previously served 18 years with Coca-Cola, joined Revlon in 2003 and Kennedy, who also worked at Coca-Cola, came to the firm in 2002 (1"The Rose Sheet" Aug. 11, 2003, In Brief and 2"The Rose Sheet" June 17, 2002, In Brief)...
You may also be interested in...
Revlon CFO
Thomas McGuire appointed exec VP and CFO, effective Aug. 18, Revlon announces Aug. 7. Reporting to President and CEO Jack Stahl, McGuire will be responsible for developing processes within the financial organization to streamline and enhance execution of the firm's growth plans, company notes. Exec previously served 18 years with Coca-Cola. McGuire succeeds Douglas Greeff, who has assumed new role as exec VP-strategic finance, company notes. In his new position, Greeff will focus on Revlon's longer term financing and strategic products...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.